Apriori Bio, Inc.
Apriori Bio is dedicated to protecting humanity against viral threats through innovative technology. They focus on developing variant-resilient vaccines and real-time insights to stay ahead of rapidly evolving viruses. Their mission is to create a world where humanity is safeguarded from viral outbreaks by predicting and designing vaccines for potential threats.
Industries
Nr. of Employees
small (1-50)
Products
Octavia
A technology platform that maps existing and potential viral variants to design vaccines and antibody drugs.
Vaccine and Antibody Drug Design
Utilizes the Octavia platform to create vaccines and antibody drugs targeting current and future viral threats.
Octavia
A technology platform that maps existing and potential viral variants to design vaccines and antibody drugs.
Vaccine and Antibody Drug Design
Utilizes the Octavia platform to create vaccines and antibody drugs targeting current and future viral threats.
News & Updates
Flagship Pioneering launches Apriori Bio to provide protection against the most significant viral threats.
Apriori Bio announces the appointment of Harry Kleanthous, Ph.D., as Chief Scientific Officer.
Apriori Bio has been recognized as a 2023 Technology Pioneer by the World Economic Forum.
Apriori Bio was included in Fast Company’s 2023 Innovation By Design Pandemic Action List.
MIT Tech Review discusses how AI is generating new drug candidates that need to be tested for efficacy.
Flagship unveils a new AI biotech platform aimed at predicting viral variants before they emerge.
Flagship Pioneering launches Apriori Bio to provide protection against the most significant viral threats.
Apriori Bio announces the appointment of Harry Kleanthous, Ph.D., as Chief Scientific Officer.
Apriori Bio has been recognized as a 2023 Technology Pioneer by the World Economic Forum.
Apriori Bio was included in Fast Company’s 2023 Innovation By Design Pandemic Action List.
MIT Tech Review discusses how AI is generating new drug candidates that need to be tested for efficacy.
Flagship unveils a new AI biotech platform aimed at predicting viral variants before they emerge.